C. R. Bard, Inc. (BCR), Monday said it entered into a definitive agreement to acquire privately-held developer and supplier of plant based hemostatic agents, Medafor, Inc., for $200 million. On specific revenue-based milestones, Bard would make future contingent payments of an additional $80 million hrough June 30, 2015. Bard expects this acquisition to add about 1 percent to revenue growth in 2014, and be a few cents dilutive to adjusted earnings per share in 2013 and neutral to 2014. The deal is expected to close later this year, and through which Bard anticipates business expansion of surgical specialties in its Davol subsidiary.
Timothy Ring, Bard's chairman and CEO, commented, "With its safety and ease of use profile, the Arista hemostat provides a great alternative to other commercially available hemostats while providing strong synergy with our Progel Sealant technology and sales channel. This technology platform represents an important building block for our surgical specialty product offering and provides a global footprint for continued expansion."
by RTT Staff Writer
For comments and feedback: email@example.com